<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006489</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAAFOA12428</org_study_id>
    <secondary_id>R01AA012428</secondary_id>
    <secondary_id>NIH grant R01-AA-012428</secondary_id>
    <nct_id>NCT00006489</nct_id>
  </id_info>
  <brief_title>Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone)</brief_title>
  <official_title>Naltrexone and Cognitive-Behavioral Therapy for Patients With Alcoholism and Post-Traumatic Stress Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate naltrexone and cognitive-behavioral therapy treatments for alcohol
      dependence and post-traumatic stress disorder (PTSD). Subjects will be randomly assigned a
      6-month treatment of either: 1) naltrexone alone, 2) naltrexone with PTSD psychosocial
      therapy, 3) a placebo with PTSD psychosocial therapy, or 4) placebo alone. An enhanced
      medication management intervention will accompany all treatment conditions. Follow-up
      assessments will be completed at 9 and 12 months after treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Posttraumatic Stress Disorder (PTSD) Symptom Scale - Interview (PSS-I-IV)</measure>
    <time_frame>Week 0 (Pretreatment), Week 24 (Posttreatment), Week 52 (Follow-up)</time_frame>
    <description>The PSS-I-IV is a clinician-rated interview that evaluates PTSD symptoms on a frequency/severity scale corresponding to the DSM-IV symptom criteria. The measure has a total score range from 0 to 51, with higher scores indicating more severe PTSD symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drinking Timeline Follow-back Interview (TFBI)</measure>
    <time_frame>Week 0 (Pretreatment), Week 24 (Posttreatment), Week 52 (Follow-up)</time_frame>
    <description>The TFBI is an interview that utilizes a calendar method to assess when and how much alcohol was consumed by the participant. At Week 0 (Pretreatment), Week 24 (Posttreatment), and Week 52 (Follow-up), alcohol consumed in the past 90 days was assessed. This measure was then used to calculate the percentage of days drinking in the past 90 days at each time point. Higher scores for percentage of days drinking indicate worse drinking outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Penn Alcohol Cravings Scale</measure>
    <time_frame>Week 0 (Pretreatment), Week 24 (Posttreatment), Week 52 (Follow-up)</time_frame>
    <description>The Penn Alcohol Craving Scale is a 5-item self-report measure. It assesses alcohol craving during the prior week. Total scores on this measure range from 0 to 30, with higher scores indicating a higher level of craving.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Alcoholism</condition>
  <condition>Alcohol Dependence</condition>
  <condition>Post-Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Naltrexone alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naltrexone alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone with CBT for PTSD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naltrexone with CBT for PTSD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with CBT for PTSD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo with CBT for PTSD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive-Behavioral Therapy</intervention_name>
    <description>Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week</description>
    <arm_group_label>Naltrexone with CBT for PTSD</arm_group_label>
    <arm_group_label>Placebo with CBT for PTSD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>Daily dosing 100 mg for 24 weeks</description>
    <arm_group_label>Naltrexone alone</arm_group_label>
    <arm_group_label>Naltrexone with CBT for PTSD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pill Placebo daily dosing 24 weeks</description>
    <arm_group_label>Placebo alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets criteria for alcohol dependence and post-traumatic stress disorder.

          -  Heavy drinking in the past 30 days (an average of more than 12 alcohol drinks per week
             with at least 1 day of 4 or more drinks).

          -  Successfully complete medical detoxification.

          -  Exhibit clinically significant trauma-related symptoms.

          -  Live in a commutable distance to the University of Pennsylvania and agree to follow-up
             visits.

          -  Aged between 18 and 65 years old.

          -  Able to provide an informed consent.

          -  Speak and read English.

        Exclusion Criteria:

          -  Current diagnosis of any substance dependence other than alcohol, nicotine, or
             cannabis.

          -  Evidence of opiate use in the past 30 days.

          -  Significant risk of violence or history of serious violent behavior during the past
             year.

          -  Continued contact with an intimate partner if assault by the partner is the index
             trauma.

          -  Changes in dosage or medication for any SSRI treatment in the three months prior to
             entering the study.

          -  Unstable or serious medical illness.

          -  Current severe psychiatric symptom.

          -  Mental retardation or another pervasive developmental disorder.

          -  Use of an investigational medication in the past 30 days.

          -  Pregnant, nursing or not using reliable contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edna B. Foa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Anxiety, University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2000</study_first_submitted>
  <study_first_submitted_qc>November 8, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2000</study_first_posted>
  <results_first_submitted>November 21, 2016</results_first_submitted>
  <results_first_submitted_qc>March 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 21, 2017</results_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcoholism</keyword>
  <keyword>Alcohol Dependence</keyword>
  <keyword>Post-Traumatic Stress Disorder</keyword>
  <keyword>Naltrexone</keyword>
  <keyword>Cognitive Behavior Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Naltrexone + Supportive Counseling</title>
          <description>Naltrexone alone
Naltrexone: Daily dosing 100 mg for 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Naltrexone + CBT (Prolonged Exposure Therapy)</title>
          <description>Naltrexone with CBT for PTSD
Cognitive-Behavioral Therapy: Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week
Naltrexone: Daily dosing 100 mg for 24 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo + CBT (Prolonged Exposure Therapy)</title>
          <description>Placebo with CBT for PTSD
Cognitive-Behavioral Therapy: Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week</description>
        </group>
        <group group_id="P4">
          <title>Placebo + Supportive Counseling</title>
          <description>Placebo alone
Placebo: Pill Placebo daily dosing 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Scheduling Conflict</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Naltrexone + Supportive Counseling</title>
          <description>Naltrexone alone
Naltrexone: Daily dosing 100 mg for 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Naltrexone + CBT (Prolonged Exposure Therapy)</title>
          <description>Naltrexone with CBT for PTSD
Cognitive-Behavioral Therapy: Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week
Naltrexone: Daily dosing 100 mg for 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo + CBT (Prolonged Exposure Therapy)</title>
          <description>Placebo with CBT for PTSD
Cognitive-Behavioral Therapy: Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week</description>
        </group>
        <group group_id="B4">
          <title>Placebo + Supportive Counseling</title>
          <description>Placebo alone
Placebo: Pill Placebo daily dosing 24 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="43"/>
            <count group_id="B5" value="165"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.9" lower_limit="24" upper_limit="63"/>
                    <measurement group_id="B2" value="40.1" lower_limit="19" upper_limit="64"/>
                    <measurement group_id="B3" value="44.7" lower_limit="23" upper_limit="62"/>
                    <measurement group_id="B4" value="41.2" lower_limit="24" upper_limit="58"/>
                    <measurement group_id="B5" value="42.7" lower_limit="19" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Types of trauma</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Sexual Assault</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Assault</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Combat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Posttraumatic Stress Disorder (PTSD) Symptom Scale - Interview (PSS-I-IV)</title>
        <description>The PSS-I-IV is a clinician-rated interview that evaluates PTSD symptoms on a frequency/severity scale corresponding to the DSM-IV symptom criteria. The measure has a total score range from 0 to 51, with higher scores indicating more severe PTSD symptoms.</description>
        <time_frame>Week 0 (Pretreatment), Week 24 (Posttreatment), Week 52 (Follow-up)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone + Supportive Counseling</title>
            <description>Naltrexone alone
Naltrexone: Daily dosing 100 mg for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone + CBT (Prolonged Exposure Therapy)</title>
            <description>Naltrexone with CBT for PTSD
Cognitive-Behavioral Therapy: Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week
Naltrexone: Daily dosing 100 mg for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo + CBT (Prolonged Exposure Therapy)</title>
            <description>Placebo with CBT for PTSD
Cognitive-Behavioral Therapy: Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week</description>
          </group>
          <group group_id="O4">
            <title>Placebo + Supportive Counseling</title>
            <description>Placebo alone
Placebo: Pill Placebo daily dosing 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Posttraumatic Stress Disorder (PTSD) Symptom Scale - Interview (PSS-I-IV)</title>
          <description>The PSS-I-IV is a clinician-rated interview that evaluates PTSD symptoms on a frequency/severity scale corresponding to the DSM-IV symptom criteria. The measure has a total score range from 0 to 51, with higher scores indicating more severe PTSD symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pretreatment (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" lower_limit="24.7" upper_limit="30.8"/>
                    <measurement group_id="O2" value="30.3" lower_limit="27.7" upper_limit="32.9"/>
                    <measurement group_id="O3" value="27.7" lower_limit="24.7" upper_limit="30.8"/>
                    <measurement group_id="O4" value="27.5" lower_limit="25.4" upper_limit="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posttreatmwent (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" lower_limit="12.2" upper_limit="18.3"/>
                    <measurement group_id="O2" value="12.2" lower_limit="8.2" upper_limit="16.1"/>
                    <measurement group_id="O3" value="13.3" lower_limit="9.3" upper_limit="17.3"/>
                    <measurement group_id="O4" value="15.5" lower_limit="12.4" upper_limit="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (Week 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" lower_limit="7.2" upper_limit="14.6"/>
                    <measurement group_id="O2" value="7.9" lower_limit="4.1" upper_limit="11.8"/>
                    <measurement group_id="O3" value="10.8" lower_limit="6.3" upper_limit="15.2"/>
                    <measurement group_id="O4" value="11.1" lower_limit="8.2" upper_limit="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Drinking Timeline Follow-back Interview (TFBI)</title>
        <description>The TFBI is an interview that utilizes a calendar method to assess when and how much alcohol was consumed by the participant. At Week 0 (Pretreatment), Week 24 (Posttreatment), and Week 52 (Follow-up), alcohol consumed in the past 90 days was assessed. This measure was then used to calculate the percentage of days drinking in the past 90 days at each time point. Higher scores for percentage of days drinking indicate worse drinking outcomes.</description>
        <time_frame>Week 0 (Pretreatment), Week 24 (Posttreatment), Week 52 (Follow-up)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone + Supportive Counseling</title>
            <description>Naltrexone alone
Naltrexone: Daily dosing 100 mg for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone + CBT (Prolonged Exposure Therapy)</title>
            <description>Naltrexone with CBT for PTSD
Cognitive-Behavioral Therapy: Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week
Naltrexone: Daily dosing 100 mg for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo + CBT (Prolonged Exposure Therapy)</title>
            <description>Placebo with CBT for PTSD
Cognitive-Behavioral Therapy: Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week</description>
          </group>
          <group group_id="O4">
            <title>Placebo + Supportive Counseling</title>
            <description>Placebo alone
Placebo: Pill Placebo daily dosing 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Drinking Timeline Follow-back Interview (TFBI)</title>
          <description>The TFBI is an interview that utilizes a calendar method to assess when and how much alcohol was consumed by the participant. At Week 0 (Pretreatment), Week 24 (Posttreatment), and Week 52 (Follow-up), alcohol consumed in the past 90 days was assessed. This measure was then used to calculate the percentage of days drinking in the past 90 days at each time point. Higher scores for percentage of days drinking indicate worse drinking outcomes.</description>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pretreatment (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4" lower_limit="67.1" upper_limit="83.5"/>
                    <measurement group_id="O2" value="71.2" lower_limit="62.5" upper_limit="79.9"/>
                    <measurement group_id="O3" value="78.6" lower_limit="71.4" upper_limit="85.6"/>
                    <measurement group_id="O4" value="74.1" lower_limit="66.4" upper_limit="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posttreatmwent (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0.1" upper_limit="6.8"/>
                    <measurement group_id="O2" value="7.3" lower_limit="1.9" upper_limit="12.7"/>
                    <measurement group_id="O3" value="13.4" lower_limit="5.5" upper_limit="21.1"/>
                    <measurement group_id="O4" value="13.2" lower_limit="7.3" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (Week 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" lower_limit="10.6" upper_limit="32.4"/>
                    <measurement group_id="O2" value="8.8" lower_limit="3.3" upper_limit="14.3"/>
                    <measurement group_id="O3" value="18.9" lower_limit="8.8" upper_limit="29.1"/>
                    <measurement group_id="O4" value="27.3" lower_limit="14.7" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Penn Alcohol Cravings Scale</title>
        <description>The Penn Alcohol Craving Scale is a 5-item self-report measure. It assesses alcohol craving during the prior week. Total scores on this measure range from 0 to 30, with higher scores indicating a higher level of craving.</description>
        <time_frame>Week 0 (Pretreatment), Week 24 (Posttreatment), Week 52 (Follow-up)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone + Supportive Counseling</title>
            <description>Naltrexone alone
Naltrexone: Daily dosing 100 mg for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone + CBT (Prolonged Exposure Therapy)</title>
            <description>Naltrexone with CBT for PTSD
Cognitive-Behavioral Therapy: Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week
Naltrexone: Daily dosing 100 mg for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo + CBT (Prolonged Exposure Therapy)</title>
            <description>Placebo with CBT for PTSD
Cognitive-Behavioral Therapy: Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week</description>
          </group>
          <group group_id="O4">
            <title>Placebo + Supportive Counseling</title>
            <description>Placebo alone
Placebo: Pill Placebo daily dosing 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Penn Alcohol Cravings Scale</title>
          <description>The Penn Alcohol Craving Scale is a 5-item self-report measure. It assesses alcohol craving during the prior week. Total scores on this measure range from 0 to 30, with higher scores indicating a higher level of craving.</description>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pretreatment (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" lower_limit="15.3" upper_limit="20.0"/>
                    <measurement group_id="O2" value="17.9" lower_limit="15.8" upper_limit="20.1"/>
                    <measurement group_id="O3" value="19.2" lower_limit="16.3" upper_limit="22.1"/>
                    <measurement group_id="O4" value="18.7" lower_limit="16.7" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posttreatmwent (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="6.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="5.1" lower_limit="3.4" upper_limit="6.7"/>
                    <measurement group_id="O3" value="9.1" lower_limit="6.1" upper_limit="12.2"/>
                    <measurement group_id="O4" value="10.3" lower_limit="8.2" upper_limit="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (Week 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="4.2" upper_limit="10.6"/>
                    <measurement group_id="O2" value="6.0" lower_limit="4.0" upper_limit="8.1"/>
                    <measurement group_id="O3" value="6.9" lower_limit="4.2" upper_limit="9.7"/>
                    <measurement group_id="O4" value="8.9" lower_limit="6.4" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected throughout time of participant enrollment and involvement in the study. Participant enrollment began on February 8, 2001 and ended on June 25, 2009. Data collection was completed on August 12, 2010. Therefore, adverse event data were collected for 9 years, 6 months.</time_frame>
      <desc>Please Note: None of the Serious Adverse events were determined to be related to the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Naltrexone + Supportive Counseling</title>
          <description>Naltrexone alone
Naltrexone: Daily dosing 100 mg for 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Naltrexone + CBT (Prolonged Exposure Therapy)</title>
          <description>Naltrexone with CBT for PTSD
Cognitive-Behavioral Therapy: Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week
Naltrexone: Daily dosing 100 mg for 24 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo + CBT (Prolonged Exposure Therapy)</title>
          <description>Placebo with CBT for PTSD
Cognitive-Behavioral Therapy: Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week</description>
        </group>
        <group group_id="E4">
          <title>Placebo + Supportive Counseling</title>
          <description>Placebo alone
Placebo: Pill Placebo daily dosing 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Serious Medical Illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Serious Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Psychotic Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Changes to Vision</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Issues</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Loose Stool</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Stomach Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="20" subjects_affected="10" subjects_at_risk="42"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E4" events="11" subjects_affected="7" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Increased Bowel Movements</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="7" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" events="10" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Muscle Aches</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Increased Irritability</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Stomach Virus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Edna Foa</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-746-3327</phone>
      <email>foa@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

